Product Approval / Market Authorization
Dr. Reddy’s Receives Health Canada Approval for Generic Semaglutide Injection
NSE
drreddy
BSE
500124
Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection, becoming the first company to secure marketing authorization in Canada. The approval enables commercialization in a large regulated market, strengthening its diabetes portfolio
PRICE-SENSITIVE TRIGGER
Event: Regulatory Approval (Health Canada NOC)
Type: Product Approval / Market Authorization
Impact: Positive
Immediate Effect: Enables entry into the Canadian market for Semaglutide, enhancing revenue potential and strengthening presence in regulated market
What Happened ?
Dr. Reddy’s Laboratories Limited announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.
This approval is granted under the Abbreviated New Drug Submission (ANDS) pathway and authorizes the commercialization, sale, and distribution of the drug in Canada.
key highlights
Regulatory Approval & Product Launch:
- Authority: Health Canada (Pharmaceutical Drugs Directorate)
- Approval type: Notice of Compliance (NOC)
- Product: Generic Semaglutide Injection
- Indication: Type 2 diabetes treatment (GLP-1 therapy)
- Market: Canada (regulated market)
- First company to receive approval in Canada for this generic
- Approval covers multiple dosage strengths (2 mg and 4 mg pens)
- No fixed expiry for approval
- API manufactured in-house
- Manufacturing supported by OneSource Specialty Pharma
Note:
Canada is one of the largest markets for Semaglutide globally, making this approval strategically significant
Risk Analysis
Key Risks
- Pricing pressure in generic drug markets
- Regulatory compliance and post-approval audits
- Competition from innovator and other generic players
- Dependence on successful market launch execution
- Currency and geographic market risks
Worst Case Scenario
- If market penetration is weak or pricing pressure intensifies, the expected revenue upside from this approval may be limited
Risk Level: Medium
Company Commentary
- First company to receive generic Semaglutide approval in Canada
- Strengthens presence in regulated markets
- Demonstrates capability in complex generics and peptide therapeutics
- Focus on expanding access to affordable diabetes treatment
- Commitment to reliable supply through in-house capabilities
Official Exchange Filing: Dr. Reddy’s Laboratories Limited